Clinical trial
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
NCT00491075 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00491075 |
|---|---|
| Title | Pemetrexed Plus Gemcitabine in Renal Cell Cancer |
| Official title | Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine |
| Enrollment | 16 |
| Start date | Dec 1, 2005 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Jun 25, 2007 |
| Last update posted | Apr 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: